비뇨기과 시장 : 제품 유형, 용도, 최종 사용자, 유통 채널, 기술별 - 세계 예측(2026-2032년)

The Urology Market was valued at USD 64.28 billion in 2025 and is projected to grow to USD 71.25 billion in 2026, with a CAGR of 11.74%, reaching USD 139.85 billion by 2032.

A clear and strategic orientation to the evolving urology device landscape driven by demographic shifts, clinical practice change, and accelerating technological innovation

The urology device landscape is being reshaped by converging clinical needs, demographic trends, and rapid technological innovation. Aging populations are increasing the prevalence of chronic and acute urological conditions, while care-delivery models are shifting procedures from inpatient to ambulatory settings. In parallel, advances in imaging and minimally invasive tools are changing clinical pathways and clinician expectations, prompting providers to reassess capital allocation and procurement strategies.

Consequently, manufacturers, distributors, and health systems are navigating a more complex environment where regulatory scrutiny, infection-prevention priorities, and sustainability considerations intersect. Payers and providers seek value through outcome-driven procurement and long-term service relationships, and digital channels are beginning to alter traditional distribution dynamics. Taken together, these forces demand strategic clarity about product portfolios, channel investments, and partnerships that can sustain clinical relevance and commercial performance amid accelerating change.

How minimally invasive techniques, imaging advances, single-use adoption and digital distribution are fundamentally reshaping clinical practice and commercial models in urology

Over recent years the industry has experienced transformative shifts that are redefining product lifecycles, procurement practices, and patient pathways. Minimally invasive techniques, fueled by refined imaging and laser technology, are lowering thresholds for procedural intervention and shortening length of stay, which in turn supports the continued migration of procedures to ambulatory surgical centers and outpatient clinics. Simultaneously, the adoption of single-use disposable devices has accelerated, driven by infection-control priorities, operational simplicity, and changes in total cost-of-care calculations.

At the same time, digital integration and advanced imaging modalities are enabling earlier diagnosis and more precise interventions, while artificial intelligence and enhanced visualization tools are beginning to influence device design and clinical workflows. Distribution channels are adapting as e-commerce and direct-to-provider models gain traction alongside traditional hospital procurement, creating new competitive pressures and pricing dynamics. As these shifts continue, companies that integrate cross-functional expertise-combining device innovation, service delivery, and data-driven clinical evidence-will be better positioned to capture opportunities and mitigate the operational and regulatory headwinds that accompany rapid sector transformation.

Assessing the wide-ranging operational and strategic consequences of United States tariff actions in 2025 on sourcing, production, procurement and pricing dynamics across urology devices

The cumulative effects of tariff changes implemented in 2025 in the United States have created a new set of constraints and incentives across the urology device supply chain. Manufacturers reliant on imported components have faced increased input costs, prompting many to reassess sourcing strategies and accelerate initiatives to regionalize production or qualify alternative suppliers. These adjustments have affected pricing strategies, inventory policies, and supplier contracts, leading stakeholders to re-evaluate long-term supplier relationships and contractual flexibility.

Healthcare providers and distributors have responded by intensifying negotiations, prioritizing value-based purchasing, and increasing scrutiny of total cost implications, including service and consumable components. In addition, some device makers have shifted higher-value assembly and final testing to domestic facilities to reduce exposure to tariff volatility and to maintain more predictable lead times. Regulatory compliance and customs complexity have added administrative burdens, which in turn favor larger organizations with robust supply-chain functions. Overall, the tariff environment has accelerated structural adjustments in sourcing, production footprints, and commercial terms, prompting both near-term operational responses and longer-term strategic repositioning among manufacturers and purchasers.

Deep segmentation framework highlighting product, application, end-user, channel and technology distinctions that drive clinical utility, procurement behavior and commercial strategy

A granular view of segmentation reveals differentiated demand, clinical utility, and procurement behavior across product, application, end-user, distribution, and technology dimensions. By product type, the landscape separates into disposable devices and reusable devices, where disposable devices encompass catheters and stents; catheters further segment into Foley catheters and intermittent catheters while stents further divide into nephrostomy stents and ureteral stents. Reusable devices include endoscopes and surgical instruments, and endoscopes can be further categorized into flexible endoscopes and rigid endoscopes. These product distinctions correlate strongly with infection-control priorities, procedure volumes, and capital-investment cycles.

Applications map to distinct clinical drivers including benign prostatic hyperplasia treatment, cancer diagnosis, stone removal, and urinary incontinence management, each of which has specific clinical workflows, reimbursement considerations, and device-performance requirements. End users vary among ambulatory surgical centers, clinics, and hospitals, and each setting has unique procurement governance, budget horizons, and operational constraints. Distribution channels range across e-commerce, hospital purchases, and retail pharmacies, with digital channels progressively influencing purchasing behaviors for consumables and smaller devices. Technology segmentation encompasses imaging technology and laser technology; imaging technology itself spans CT scan, MRI, and ultrasound modalities, which inform diagnostic pathways and procedural planning. Understanding these intersecting segments enables targeted product development, differentiated sales strategies, and service models tailored to clinical needs and buyer preferences.

Regional dynamics across Americas, Europe, Middle East & Africa and Asia-Pacific shaping procurement, regulatory engagement, and supply-chain resilience for urology devices

Regional dynamics are shaping competitive priorities and investment choices across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct regulatory, reimbursement, and supply-chain contexts. In the Americas, a mix of private providers, consolidated hospital systems, and an expanding ambulatory surgical center footprint have heightened demand for devices that reduce procedure time and support same-day discharge, while distribution models reflect growing adoption of direct procurement and e-commerce for consumables.

Across Europe, the Middle East & Africa, procurement is often influenced by public payers and centralized purchasing mechanisms; cost-containment pressures coexist with a high bar for clinical evidence and reprocessing standards, which sustains the relevance of reusable equipment in some markets. In the Asia-Pacific region, rapid healthcare investment, expanding procedural volumes, and a focus on local manufacturing capacity are accelerating adoption of minimally invasive technologies, imaging upgrades, and hybrid distribution strategies. These regional distinctions imply that commercial tactics should be localized, regulatory engagement must be proactive, and supply-chain resilience tailored to each region's mix of regulatory complexity, procurement maturity, and infrastructure development.

Industry competitive dynamics driven by strategic partnerships, service-led offerings, and consolidation as players prioritize integrated solutions, aftersales and scalability

Competitive dynamics within the urology device ecosystem are increasingly characterized by strategic diversification, partnerships, and service-oriented business models. Leading manufacturers are investing in bundled solutions that combine devices with training, data services, and maintenance agreements to deepen customer relationships and create recurring revenue streams. Strategic collaborations between device makers, imaging providers, and clinical centers are accelerating validation cycles and supporting broader adoption of integrated procedural solutions.

At the same time, smaller innovators are focusing on niche indications, disposable alternatives, and technology-enabled differentiation to gain clinical traction and attract distribution partners. Consolidation activity continues as companies seek scale in manufacturing, regulatory expertise, and aftermarket service capabilities, while contract terms and service-level commitments have become central considerations in procurement decisions. In this environment, companies that align R&D priorities with clear clinical value propositions and robust post-sale support will be better positioned to secure durable contracts and navigate evolving reimbursement and procurement pressures.

Practical, high-impact actions for industry leaders to strengthen supply chains, differentiate clinically, and expand service-oriented commercial models to secure durable growth

To navigate the evolving landscape and capture sustainable growth, industry leaders should pursue a combination of supply-chain resilience, clinical differentiation, and commercial agility. First, diversifying supplier bases and regionalizing critical manufacturing steps reduces exposure to tariff volatility and protects lead times, while investments in inventory visibility and flexible contract terms improve operational resilience. Second, prioritizing product features that demonstrate measurable clinical and economic benefits-such as reduced procedure time, lower infection risk, or decreased total episode cost-will enhance procurement positioning with value-minded buyers.

Third, building service and training packages that accompany device sales increases customer retention and creates predictable revenue streams, particularly for providers shifting procedures to outpatient settings. Fourth, expanding digital and direct-to-provider distribution channels for consumables and lower-cost devices complements traditional hospital purchasing and enables faster market access. Finally, engaging proactively with regulators and payers to communicate clinical evidence and real-world outcomes will support favorable adoption and reimbursement decisions. Executed together, these actions create a defensible strategic posture grounded in operational reliability, clinical relevance, and commercial flexibility.

Robust, multi-method research methodology combining clinical literature, regulatory review, expert interviews and validation to produce actionable and verifiable industry insights

The research approach combined multi-disciplinary inputs to ensure analytical rigor, triangulation, and practical relevance. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory filings, procedural guidelines, and public policy documents to map clinical pathways, technology adoption, and compliance requirements. Primary research included structured interviews with clinicians, procurement leaders, supply-chain managers, and product developers to capture real-world operational constraints, preference drivers, and adoption barriers. Data from manufacturer technical documentation and product registries informed device specifications and functional comparisons.

Qualitative insights were validated against purchaser procurement frameworks and clinical experts to ensure alignment with practice patterns and purchasing rationales. The methodology prioritized transparency in assumptions, explicit documentation of data sources, and a layered validation process comprising internal cross-functional review and external expert validation. Limitations include variability in institutional procurement practices and the evolving nature of tariffs and regulatory guidance, which were addressed through sensitivity analyses and scenario planning to illuminate plausible strategic responses rather than singular deterministic outcomes.

Concluding synthesis of strategic priorities and urgent actions required to translate technological advances and supply-chain challenges into competitive advantage in urology

In summary, the urology device environment is at an inflection point where clinical innovation, procurement evolution, and supply-chain pressures intersect. The shift toward minimally invasive techniques, the rise of disposable options for infection control, and the integration of advanced imaging and laser technologies are reshaping clinical pathways and buyer expectations. Concurrently, tariff-driven cost dynamics and regional variations in procurement and regulatory regimes require companies to be nimble in sourcing, pricing, and commercial engagement.

Looking forward, success will depend on an integrated approach that aligns product development with clear clinical value, reinforces service and training capabilities, and builds supply-chain resilience. Providers and manufacturers who proactively adapt to outpatient migration, invest in digital and distribution flexibility, and collaborate across clinical, regulatory, and commercial functions will be better positioned to deliver improved patient outcomes while maintaining financial and operational stability. The time to act is immediate, as strategic choices made now will determine who captures advantage as the landscape continues to evolve.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urology Market, by Product Type

• 8.1. Disposable Devices
  • 8.1.1. Catheters
    • 8.1.1.1. Foley Catheters
    • 8.1.1.2. Intermittent Catheters
  • 8.1.2. Stents
    • 8.1.2.1. Nephrostomy Stents
    • 8.1.2.2. Ureteral Stents
• 8.2. Reusable Devices
  • 8.2.1. Endoscopes
    • 8.2.1.1. Flexible Endoscopes
    • 8.2.1.2. Rigid Endoscopes
  • 8.2.2. Surgical Instruments

9. Urology Market, by Application

• 9.1. Benign Prostatic Hyperplasia Treatment
• 9.2. Cancer Diagnosis
• 9.3. Stone Removal
• 9.4. Urinary Incontinence Management

10. Urology Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Clinics
• 10.3. Hospitals

11. Urology Market, by Distribution Channel

• 11.1. E-Commerce
• 11.2. Hospital Purchases
• 11.3. Retail Pharmacies

12. Urology Market, by Technology

• 12.1. Imaging Technology
  • 12.1.1. CT Scan
  • 12.1.2. MRI
  • 12.1.3. Ultrasound
• 12.2. Laser Technology

13. Urology Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Urology Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Urology Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Urology Market

17. China Urology Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Becton, Dickinson and Company
• 18.6. Boston Scientific Corporation
• 18.7. Coloplast Group
• 18.8. CONMED Corporation
• 18.9. Cook Group Incorporated
• 18.10. Dornier MedTech GmbH
• 18.11. Fujifilm Holdings Corporation
• 18.12. Intuitive Surgical, Inc.
• 18.13. Johnson & Johnson
• 18.14. Karl Storz SE & Co. KG
• 18.15. Medtronic plc
• 18.16. Olympus Corporation
• 18.17. Procept BioRobotics Corporation
• 18.18. Richard Wolf GmbH
• 18.19. Siemens Healthineers AG
• 18.20. Stryker Corporation
• 18.21. Teleflex Incorporated
• 18.22. UroViu Corporation